Ondansetron orodispersible film to prevent vomiting during pediatric radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Children with malignant tumors who are scheduled for upper abdominal or craniospinal radiotherapy will receive ondansetron orodispersible film either once or twice during treatment to compare antiemetic effect and safety. The study enrolls patients aged 1–14 with adequate blood counts and liver tests and daily radiotherapy fractions (typically 1.8 Gy). Investigators will record vomiting episodes, rescue antiemetic use, and adverse events to determine which dosing schedule is most effective and well tolerated. The goal is to define a practical clinical dosing regimen for preventing radiation-induced vomiting in this pediatric population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Children with malignant tumors diagnosed by histopathology
* Age range: 1-14 years old (calculated from the day of signing the informed consent form)
* Weight \>= 8Kg;
* Lansky functional status (LPS) score \>= 50 (excluding posterior fossa syndrome)
* Be planned to undergo upper abdominal or craniospinal radiation therapy, and the upper abdominal irradiation should cover the anatomical area from the upper edge of the 11th thoracic vertebra to the lower edge of the third lumbar vertebra
* Radiotherapy is administered once daily, and the fractional dose is 1.8Gy, except for 1.5 Gy for whole abdominal radiotherapy
* The blood routine test must meet the following criteria: ANC \>= 1.0 × 10\^9/L (after discontinuation of G-CSF), PLT \>= 50 × 10\^9/L (without drug support or transfusion therapy), HGB \>= 80g/L
* Biochemical tests must meet the following standards: total bilirubin \<= 1.5 times ULN (upper limit of normal), ALT \<= 2.5 times ULN, AST \<= 2.5 times ULN, alkaline phosphatase ≤ 1.5 times ULN, serum albumin \>= 2.5 g/dL, BUN and CRE \<= 1.5 × ULN
* Expected survival period \>= 3 months;
* The guardian of the child understands and signs the informed consent form, has good compliance, and cooperates with follow-up.

Exclusion Criteria:

* The nausea and vomiting caused by the surgery have not fully recovered if the subject has undergone a major surgery
* The patient has symptoms of central nervous system tumors such as cerebral edema and requires intervention with adrenal cortex hormones
* Participants who have participated in or are currently participating in other clinical studies within 4 weeks prior to the first use of the investigational drug (calculated based on the time of the last use of the investigational drug for those who have entered the follow-up period)
* Individuals allergic to 5-HT3 receptor antagonists or other excipients
* Joint use of apomorphine
* Congenital QT prolongation syndrome
* Severe gastrointestinal obstruction
* Other observers who affect the efficacy and adverse reactions
* Used other 5-HT3 receptor antagonists in the first 3 days of enrollment
* According to the researchers' assessment, there may be other factors that could force the subjects to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the safety of the subjects or the collection of experimental data.

Where it's running

• Chongqing University Cancer Hospital
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Principal investigator: Yue Xie — Chongqing University Cancer Hospital, Chongqing, China
• Study coordinator: Yue Xie
• Email: 344899525@qq.com
• Phone: +86 13883080833

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FaceSay: a computer program to help kids recognize facial expressions and improve social interactions

  A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.

  Recruiting Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07923370

• See how nasal ondansetron compares to IV in healthy adults

  This study tests whether a nasal spray form of ondansetron delivers similar blood levels as the IV version in healthy adults.

  Recruiting Phase 1 Nasus Pharma · Jerusalem · NCT07868861

• Access to Innovative Cancer Treatments for Children and Young People in Belgium

  This observational study collects safety and effectiveness data on off‑label and compassionate cancer medicines used in kids and young adults up to age 25 in Belgium.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Antwerp and 5 other locations · NCT07727694

• BCB-276 CAR T therapy for DIPG in children and young adults

  This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.

  Recruiting at 3 sites Phase 2 BrainChild Bio, Inc · Los Angeles, California and 5 other locations · NCT07680439

• CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes

  This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.

  Recruiting Resonance, Inc. · Yerevan and 5 other locations · NCT07632014

• Virtual reality headsets to reduce anxiety and fear during intrathecal chemotherapy in children

  This project will try virtual reality headsets with children aged 4–10 who are receiving intrathecal chemotherapy to see if they reduce anxiety, fear, and changes in vital signs.

  Recruiting TC Erciyes University · Kayseri · NCT07537062

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.